Breast Cancer Clinical Trial
Official title:
A Phase 1, Open-label, Single Center, One Period, One Sequence Study to Determine Absorption, Metabolism, and Excretion of a Single Oral Dose of Radiolabeled [14C]- SAR439859 and an Assessment of the Absolute Oral Bioavailability Using the Microdosing Technique in Healthy Post-menopausal Women
Verified date | April 2022 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objectives: - To assess the excretion balance after oral and IV administration of [14C]-SAR439859 - To assess PK of total radioactivity, [14C] -SAR439859 and its metabolite (M7) after IV administration of [14C]-SAR439859 and, PK of radioactivity, SAR439859 and M7 after oral administration of SAR439859 alone or with [14C]-SAR439859 - To assess IV clearance and absolute bioavailability of SAR439859 using microdose of [14C]-SAR439859 tracer on top of a single tablet oral dose. - To assess relative bioavailability of SAR439859 given as tablet or solution Secondary objectives: - To collect samples in order to assess metabolic profile in plasma and excreta of SAR439859 after oral administration of [14C]-SAR439859 as solution, contribution in plasma of SAR439859 and metabolite relative to total radioactivity and identify metabolites (samples will be analyzed according to metabolic analysis plan and results will be documented in a separate report). - To assess safety and tolerance of SAR439859
Status | Completed |
Enrollment | 6 |
Est. completion date | August 19, 2021 |
Est. primary completion date | August 19, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 40 Years to 75 Years |
Eligibility | Inclusion Criteria: Female participants (age between 40 and 75 years old) who are postmenopausal or had post-bilateral surgical oophorectomy not linked to a history of cancer. Participants who are overtly healthy. Body weight within 40.0 and 95.0 kg and body mass index (BMI) within the range 18.0 and 30 kg/m2 (inclusive). Capable of giving signed informed consent. Exclusion Criteria: Subject has clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Subject who had severe course of COVID-19 (i.e., hospitalization, extracorporeal membrane oxygenation, mechanically ventilated). Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month). Blood donation, any volume (usually approximately 500 mL), within 2 months before inclusion. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day). Smoking regularly more than 5 cigarettes or equivalent per week, unable to stop smoking during the study (occasional smoker can be enrolled). Excessive consumption of beverages containing xanthine bases (more than 5 cups or glasses per day). Subjects who are occupationally exposed to radiation as defined in the Ionizing Radiation Regulations 2017. Participation in a trial with [13C] or [14C] radiolabeled medication in the 12 months preceding the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Investigational Site Number 8260001 | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administration | Day 1 to Day 6 | ||
Primary | Percentage of radioactive dose excreted in urine and feces after oral administration | Day 7 up to max Day 44 | ||
Primary | Assessment of Pharmacokinetic (PK) parameter: AUC for radioactivity and SAR439859 after IV administration | Area under the plasma concentration versus time curve extrapolated to infinity | Day 1 to Day 3 | |
Primary | Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after IV administration | Terminal half-life associated with the terminal slope (?z) | Day 1 to Day 3 | |
Primary | Assessment of PK parameter: CL for SAR439859 after IV administration | Total body clearance | Day 1 to Day 3 | |
Primary | Assessment of PK parameter: AUC ratios after IV administration | SAR439859 to radioactivity ratio for plasma AUC | Day 1 to Day 3 | |
Primary | Assessment of PK parameter: Cmax for radioactivity and SAR439859 after oral administration | Maximum plasm concentration observed | Day 1 to Day 5, Day 7 to Day 11 | |
Primary | Assessment of PK parameter: tmax for radioactivity and SAR439859 after oral administration | Time to reach Cmax | Day 1 to Day 5, Day 7 to Day 11 | |
Primary | Assessment of PK parameter: AUC for radioactivity and SAR439859 after oral administration | Day 1 to Day 5, Day 7 to Day 11 | ||
Primary | Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after oral administration | Day 1 to Day 5, Day 7 to Day 11 | ||
Primary | Assessment of PK parameter: AUC ratios after oral administration | SAR439859 to radioactivity ratio for plasma AUC | Day 7 to Day 11 | |
Primary | Assessment of PK parameter: Cmax for M7 after IV and oral administration | Day 1 to Day 5, Day 7 to Day 11 | ||
Primary | Assessment of PK parameter: AUC for M7 after IV and oral administration | Day 1 to Day 5, Day 7 to Day 11 | ||
Primary | Assessment of PK parameter: t1/2z for M7 after IV and oral administration | Day 1 to Day 5, Day 7 to Day 11 | ||
Primary | Assessment of PK parameter: Rmet Cmax after IV and oral administration | M7 to SAR439859 ratio for plasma Cmax | Day 1 to Day 5, Day 7 to Day 11 | |
Primary | Assessment of PK parameter: Rmet AUC after IV and oral administration | M7 to SAR439859 ratio for plasma AUC | Day 1 to Day 5, Day 7 to Day 11 | |
Primary | Absolute oral bioavailability of SAR439859 | Absolute oral bioavailability, expressed as a percentage, estimated from AUCs obtained after oral and IV administration | Day 1 to Day 5, Day 7 to Day 11 | |
Primary | Relative bioavailability of SAR439859 after oral administration | Day 1 to Day 5, Day 7 to Day 11 | ||
Secondary | Number of participants with adverse events | Day 1 to Day 44 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |